These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30936218)

  • 1. Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer.
    Leick M; Maus MV
    Cancer Discov; 2019 Apr; 9(4):466-468. PubMed ID: 30936218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor transduced T cells: Tuning up for the next generation.
    Schubert ML; Hoffmann JM; Dreger P; Müller-Tidow C; Schmitt M
    Int J Cancer; 2018 May; 142(9):1738-1747. PubMed ID: 29119551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
    Abken H
    Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
    Zhou SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical management of side effects related to CAR T cell therapy in hematologic malignancies.
    Namuduri M; Brentjens RJ
    Expert Rev Hematol; 2016 Jun; 9(6):511-3. PubMed ID: 27139507
    [No Abstract]   [Full Text] [Related]  

  • 9. Current status of chimeric antigen receptor therapy for haematological malignancies.
    Maude S; Barrett DM
    Br J Haematol; 2016 Jan; 172(1):11-22. PubMed ID: 26560054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.
    Kiesgen S; Chicaybam L; Chintala NK; Adusumilli PS
    J Thorac Oncol; 2018 Jan; 13(1):16-26. PubMed ID: 29107016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race.
    Harrer DC; Dörrie J; Schaft N
    Hum Gene Ther; 2018 May; 29(5):547-558. PubMed ID: 29320890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
    Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
    Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
    Magee MS; Snook AE
    Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
    Chmielewski M; Hombach AA; Abken H
    Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review].
    Cheng X; Wang YJ; Feng S; Wu YY; Yang TH; Lai X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):626-630. PubMed ID: 29665944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.